FibroBiologics (FBLG) Non Operating Income (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Non Operating Income of -$84000.0 for Q2 2026, up 50.0% year-over-year from -$56000.0 in Q2 2025, and down 223.53% on a QoQ basis from $68000.0 in Q1 2026.
FibroBiologics (FBLG) Non Operating Income (2023 - 2026) Analysis & Trends
FibroBiologics has reported Non Operating Income for 4 years, with the latest figure at -$84000.0 in Q2 2026.
- Non Operating Income for Q2 2026 came in at -$84000.0, up 50.0% year-over-year; the trailing twelve-month figure through Jun 2026 was -$1.4 million (down 149.27% YoY), and the FY2025 annual result was -$2.0 million, down 177.52% from the prior year.
- Non Operating Income eased to -$84000.0 in Q2 2026, from $68000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $2.9 million in Q3 2024 and troughed at -$740000.0 in Q3 2025.
- A 4-year average of $99363.6 and a median of -$141000.0 in 2023 frame the typical range for Non Operating Income.
- The widest annual swing landed in 2024, when Non Operating Income jumped 2122.7%; it then plunged 206.69% in 2025.
- A 4-year view of Non Operating Income shows it stood at -$203000.0 in 2023, then surged by 401.97% to $613000.0 in 2024, then plunged by 206.69% to -$654000.0 in 2025, then soared by 87.16% to -$84000.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were -$84000.0 in Q2 2026, $68000.0 in Q1 2026, and -$654000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - | -84,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -84,000.00 |
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | -654,000.00 |
| Sep 30, 2025 | -740,000.00 |
| Mar 31, 2025 | -435,000.00 |
| Dec 31, 2024 | 613,000.00 |
| Sep 30, 2024 | 2.85 Mn |
| Dec 31, 2023 | -203,000.00 |
| Sep 30, 2023 | -141,000.00 |
| Mar 31, 2023 | -15,000.00 |